Table 3.
Therapy, outcomes and diagnosis by virus.
| SARS-CoV-2 | Non-SARS-CoV-2 virus | Absolute difference (95% CI) | p value | |
|---|---|---|---|---|
| n = 194 | n = 533 | |||
|
Therapy Antibiotics used |
176 (91%) | 475 (89%) | 2.1% (−2.9% to 7.1%) | 0.317 |
| Outcome | ||||
| ICU admission | 36 (19%) | 9 (2%) | 16.9% (12.9% to 20.8%) | <0.0001 |
| In hospital mortality to 30 days | 41 (21%) | 8 (2%) | 19.7% (15.6% to 23.9%) | <0.0001 |
| 30-day mortality | 47a (26%) | 9 (2%) | 23.9% (19.4% to 28.4%) | <0.0001 |
| Readmission | 15b (12%) | 35 (7%) | 5.0% (−0.1% to 10.2%) | 0.065 |
| Investigator final diagnosis | ||||
| Pneumonia | 156 (81%) | 125 (24%) | 57.3% (49.3% to 65.3%) | <0.0001 |
| Influenza like illness | 18 (9%) | 114 (21%) | −12.1% (−18.5% to −5.8%) | 0.0002 |
| Non-pneumonic lower respiratory tract infection | 15 (8%) | 67 (13%) | −4.8% (−10.1% to 0.4%) | 0.069 |
| Exacerbation asthma | 1 (1%) | 106 (20%) | −19.4% (−25.3% to −13.6%) | <0.0001 |
| Exacerbation COPD | 1 (1%) | 91 (17%) | −16.6% (−22.1% to −11.1%) | <0.0001 |
| Exacerbation other underlying respiratory disease | 1 (1%) | 17 (3%) | −2.7% (−5.3% to 0%) | 0.055 |
| Other | 1 (1%) | 11 (2%) | −1.6% (−3.7% to 0.6%) | 0.198 |
Data are n (%).
a
n=145.
b
n=128.
COPD, Chronic obstructive pulmonary disease.